| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e0729c72324fb5472d707d13dadb4dc |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-20 |
| filingDate |
2014-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4925b57efcffddd9717385c3f0081da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d875325eefe9e78e21539898764668d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_400c36e5014e399cc6850f88056c6c4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5221cf8203d4353a2edcf2ae985a3ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72d37e7c89ec94bbab33b00b7f1db5b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b75cfed8b1e0732211cb27f5e73baf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e38a75d093faf38f01aa5852e97fc5f6 |
| publicationDate |
2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9884821-B2 |
| titleOfInvention |
N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| abstract |
The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10252996-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021113497-A1 |
| priorityDate |
2013-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |